Home » Our work » Medicines Management » Policies, guidelines & legacy documents » Medicines Management Commissioning Policies
Medicines Management Commissioning Policies
- CGM for Children and Young People aged under 18 years with Type 1 and Type 2 diabetes
- CGM for Adults with insulin-treated diabetes (including pregnancy)
- Medicines and Pharmacy Strategy 2023 Final
- 20230621 Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy V2 (002)
- Drugs used on Primary Care for the treatment of erectile dysfunction (ED)
- Safety pen needles and safety lancet devices - Commissioning Statement-NHS STW V4
- Individual Funding Request Policy (IFR)
- Individual Funding Request application form
- Funding for Experimental and Unproven Treatments
- On-going access to treatment following a trial of treatment which has not been sanctioned by NHS STW
- On-going access to treatment following the completion of a trial explicitly funded by NHS STW
- On-going access to treatment following the completion of industry sponsored clinical trials or funding.
- On-going access to treatment following the completion of non-commercially funded clinical trials
- Ethical framework for priority setting and resource allocation allocation
- 20232809 NHSSTW Management of Patient Group Directions (PGDs) policy v1.0 final
- NHS Shropshire Telford & Wrekin Liothyronine Policy V2
- NHS Shropshire Telford & Wrekin Primary Care Rebates April 2024
- Continuous Subcutaneous Insulin Infusion (CSII) without CGM in adults and children with Type 1 Diabetes
- STW Gluten Free Statement
- Botulinum Toxin Policy
- Non-Medical Prescribing Policy Feb 2022
- Insulin degludec for Type 1 and restricted use in Type 2 diabetes
- Bath and Shower preparations in Primary Care Policy V2